Gender Differences in Diagnosis, Prevention, and Treatment of Cardiotoxicity in Cardio-Oncology

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Sep 9

PMID 36079097

Authors

Shawn Simek

Brian Lue

Anjali Rao

Goutham Ravipati

Srilakshmi Vallabhaneni

Kathleen Zhang

Vlad G Zaha

Alvin Chandra

Affiliations

Soon will be listed here.

Abstract

Gender differences exist throughout the medical field and significant progress has been made in understanding the effects of gender in many aspects of healthcare. The field of cardio-oncology is diverse and dynamic with new oncologic and cardiovascular therapies approved each year; however, there is limited knowledge regarding the effects of gender within cardio-oncology, particularly the impact of gender on cardiotoxicities. The relationship between gender and cardio-oncology is unique in that gender likely affects not only the biological underpinnings of cancer susceptibility, but also the response to both oncologic and cardiovascular therapies. Furthermore, gender has significant socioeconomic and psychosocial implications which may impact cancer and cardiovascular risk factor profiles, cancer susceptibility, and the delivery of healthcare. In this review, we summarize the effects of gender on susceptibility of cancer, response to cardiovascular and cancer therapies, delivery of healthcare, and highlight the need for further gender specific studies regarding the cardiovascular effects of current and future oncological treatments.

Citing Articles

Cardiotoxicity in Cancer Patients: The Prevalence, Risk Factors, and Cardioprotective Measures in a Cancer Centre in Saudi Arabia.

Badheeb A, Alhosni Y, Alshahrani M, Asery T, Al Nasher S, Seada I Cureus. 2024; 16(5):e59608.

PMID: 38832203 PMC: 11144837. DOI: 10.7759/cureus.59608.

[Gender-specific differences in cardiology].

Sandek A, Hasenfuss G Inn Med (Heidelb). 2022; 64(8):727-735.

PMID: 36456657 DOI: 10.1007/s00108-022-01437-2.

References

Hernandez R, Sorensen H, Pedersen L, Jacobsen J, Lash T . Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009; 115(19):4442-9. DOI: 10.1002/cncr.24508. View

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280(7):605-13. DOI: 10.1001/jama.280.7.605. View

Mauvais-Jarvis F, Merz N, Barnes P, Brinton R, Carrero J, DeMeo D . Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020; 396(10250):565-582. PMC: 7440877. DOI: 10.1016/S0140-6736(20)31561-0. View

Lipshultz S, Lipsitz S, Mone S, Goorin A, Sallan S, Sanders S . Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995; 332(26):1738-43. DOI: 10.1056/NEJM199506293322602. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Shannon G, Jansen M, Williams K, Caceres C, Motta A, Odhiambo A . Gender equality in science, medicine, and global health: where are we at and why does it matter?. Lancet. 2019; 393(10171):560-569. DOI: 10.1016/S0140-6736(18)33135-0. View

Le Marchand L . The predominance of the environment over genes in cancer causation: implications for genetic epidemiology. Cancer Epidemiol Biomarkers Prev. 2005; 14(5):1037-9. DOI: 10.1158/1055-9965.EPI-04-0816. View

Klein S . Immune cells have sex and so should journal articles. Endocrinology. 2012; 153(6):2544-50. PMC: 3359602. DOI: 10.1210/en.2011-2120. View

Pradhan A, Olsson P . Sex differences in severity and mortality from COVID-19: are males more vulnerable?. Biol Sex Differ. 2020; 11(1):53. PMC: 7498997. DOI: 10.1186/s13293-020-00330-7. View

10.

Ali I, Hogberg J, Hsieh J, Auerbach S, Korhonen A, Stenius U . Gender differences in cancer susceptibility: role of oxidative stress. Carcinogenesis. 2016; 37(10):985-992. PMC: 6276900. DOI: 10.1093/carcin/bgw076. View

11.

Hamberg K, Risberg G, Johansson E . Male and female physicians show different patterns of gender bias: a paper-case study of management of irritable bowel syndrome. Scand J Public Health. 2004; 32(2):144-52. DOI: 10.1080/14034940310015401. View

12.

Arber S, McKinlay J, Adams A, Marceau L, Link C, ODonnell A . Patient characteristics and inequalities in doctors' diagnostic and management strategies relating to CHD: a video-simulation experiment. Soc Sci Med. 2005; 62(1):103-15. DOI: 10.1016/j.socscimed.2005.05.028. View

13.

Zhu D, Chung H, Dobson A, Pandeya N, Giles G, Bruinsma F . Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019; 4(11):e553-e564. PMC: 7118366. DOI: 10.1016/S2468-2667(19)30155-0. View

14.

Giacomoni P, Mammone T, Teri M . Gender-linked differences in human skin. J Dermatol Sci. 2009; 55(3):144-9. DOI: 10.1016/j.jdermsci.2009.06.001. View

15.

Khalid Y, Fradley M, Dasu N, Dasu K, Shah A, Levine A . Gender disparity in cardiovascular mortality following radiation therapy for Hodgkin's lymphoma: a systematic review. Cardiooncology. 2020; 6:12. PMC: 7405444. DOI: 10.1186/s40959-020-00067-7. View

16.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

17.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

18.

Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski J . Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017; 3(3):163-182. DOI: 10.1093/ehjcvp/pvw042. View

19.

Zucker I, Prendergast B . Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020; 11(1):32. PMC: 7275616. DOI: 10.1186/s13293-020-00308-5. View

20.

Luca F, Abrignani M, Parrini I, Di Fusco S, Giubilato S, Rao C . Update on Management of Cardiovascular Diseases in Women. J Clin Med. 2022; 11(5). PMC: 8911459. DOI: 10.3390/jcm11051176. View